Patents Assigned to Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
-
Patent number: 10310140Abstract: A method for forecasting an environmental event/a type of environmental event includes acquiring at least one test data set of at least one behavioral and/or physiological parameter of a population of animals; generating a test profile based on said at least one test data set, representing behavior and/or physiological status of the population of animals; calculating a ratio between the test profile and a first reference profile; and setting an alert, if said ratio reaches a predefined threshold value.Type: GrantFiled: May 8, 2013Date of Patent: June 4, 2019Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Martin Wikelski, Uschi Müller, Wolfgang Arne Heidrich, Franz Xaver Kümmeth
-
Publication number: 20190161534Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.Type: ApplicationFiled: August 11, 2017Publication date: May 30, 2019Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN
-
Publication number: 20190153077Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.Type: ApplicationFiled: August 11, 2017Publication date: May 23, 2019Applicants: ARSANIS Biosciences GmbH, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.Inventors: Valeria SZIJÁRTO, Gábor NAGY, Luis GUACHALLA, Katharina RAMONI, Adriana BADARAU, Eszter NAGY, Tim ROLLENSKE, Hedda WARDEMANN, Irina MIRKINA
-
Publication number: 20190144853Abstract: The present invention relates to a method for producing a panel of cells (i.e. a cell library) expressing various different mutant variants of a protein of interest, wherein only one of said mutant variants is expressed per cell from a single gene copy. The present invention also relates to a method or cell library for identifying a mutant variant of a protein of interest having a different or modified biological activity as compared to the corresponding wild-type protein of interest. According to the present invention the identified mutant variant of a protein of interest may be applied for white biotechnology.Type: ApplicationFiled: July 31, 2017Publication date: May 16, 2019Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: David Ng, Oliver Griesbeck, Mutlu Erdogan
-
Patent number: 10246413Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.Type: GrantFiled: September 13, 2017Date of Patent: April 2, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Steffen Gaali, Felix Hausch, Alexander Kirschner, Xixi Feng, Andreas Bracher, Gerd Ruehter
-
Patent number: 10241539Abstract: A solution for synchronizing a network comprising a plurality of interconnected nodes provides a stable synchronized state, especially for large scale networks. Signal transmission speed and the length of each interconnection of the network is configured to cause a delay of the signals received by a node from the other node of the interconnection which is larger than one millionth of the free-running period of the controllable oscillator of the receiving node such that Network-wide synchronization of oscillators is achieved for all nodes of the network in a continuous self-organized process in interaction with the other node of the network.Type: GrantFiled: June 22, 2015Date of Patent: March 26, 2019Assignees: TECHNISCHE UNIVERSITAT DRESDEN, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.Inventors: Lucas Wetzel, Frank Jülicher, David Josef Jörg, Gerhard Fettweis, Wolfgang Rave, Alexandros Pollakis
-
Patent number: 10220083Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: September 28, 2015Date of Patent: March 5, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Benjamin Schumann, Sharavathi Guddehalli Parameswarappa, Heung Sik Hahm, Subramanian Govindan
-
Patent number: 10221439Abstract: The invention relates to the in vitro and in cellulo detection of the cofactors nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). Provided is a sensor molecule for fluorescence- or luminescence-based detection of a nicotinamide adenine dinucleotide analyte, in particular for detecting the concentrations of NAD+, NADP+ and/or the ratios of the concentrations of NAD+/NADH and NADP+/NADPH, the sensor comprising (i) a binding protein (BP) for the nicotinamide adenine dinucleotide analyte, the BP being derived from sepiapterin reductase (SPR; EC 1.1.1.153) (ii) an SPR ligand (SPR-L) capable of intramolecular binding to said BP in the presence of the oxidized form of said analyte; and (iii) at least one fluorophore.Type: GrantFiled: February 16, 2016Date of Patent: March 5, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Olivier Sallin, Luc Reymond, Kai Peter Johnsson
-
Publication number: 20190052892Abstract: A method for encoding high dynamic range (HDR) images involves providing a lower dynamic range (LDR) image, generating a prediction function for estimating the values for pixels in the HDR image based on the values of corresponding pixels in the LDR image, and obtaining a residual frame based on differences between the pixel values of the HDR image and estimated pixel values. The LDR image, prediction function and residual frame can all be encoded in data from which either the LDR image of HDR image can be recreated.Type: ApplicationFiled: October 15, 2018Publication date: February 14, 2019Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Alexander EFREMOV, Rafal MANTIUK, Grzegorz KRAWCZYK, Karol MYSZKOWSKI, Hans-Peter SEIDEL
-
Patent number: 10188718Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.Type: GrantFiled: May 15, 2015Date of Patent: January 29, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Peter H. Seeberger, Claney Lebev Pereira, Chakkumkal Anish, Andreas Geissner
-
Patent number: 10190168Abstract: The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and/or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and/or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and/or CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.Type: GrantFiled: June 16, 2014Date of Patent: January 29, 2019Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V.Inventors: Florian Holsboer, Bertram Müller-Myhsok
-
Patent number: 10165297Abstract: A method for encoding high dynamic range (HDR) images involves providing a lower dynamic range (LDR) image, generating a prediction function for estimating the values for pixels in the HDR image based on the values of corresponding pixels in the LDR image, and obtaining a residual frame based on differences between the pixel values of the HDR image and estimated pixel values. The LDR image, prediction function and residual frame can all be encoded in data from which either the LDR image of HDR image can be recreated.Type: GrantFiled: November 30, 2017Date of Patent: December 25, 2018Assignee: Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.Inventors: Alexander Efremov, Rafal Mantiuk, Grzegorz Krawczyk, Karol Myszkowski, Hans-Peter Seidel
-
Patent number: 10134498Abstract: A plasmon generator comprises a plasmon supporting surface and first and second quantum systems respectively defining first and second quantum states with a tunneling junction being present between the first and second quantum systems, the first and second quantum systems being present in an electric circuit to generate a tunneling current between the first and second quantum systems, whereby electrons tunneling between said first and second quantum states loose energy in the process and generate plasmons at the plasmon supporting surface.Type: GrantFiled: November 28, 2014Date of Patent: November 20, 2018Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V., KING'S COLLEGE LONDONInventors: Alexander Kabakchiev, Theresa Lutz, Christoph Grosse, Uta Schlickum, Klaus Kuhnke, Klaus Kern, Alessandro De Vita
-
Patent number: 10071966Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.Type: GrantFiled: December 22, 2015Date of Patent: September 11, 2018Assignees: LUDWIG-MAXIMALIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick, Markus Geissen, Martin H. Groschup, Jens Wagner
-
Publication number: 20180246062Abstract: The present invention relates to a method for determining in an expedient manner and with minimal sample consumption the structure of an unknown carbohydrate by using ion mobility-mass spectrometry (IM-MS) in negative ionization mode and fragmentation and a database containing structures of carbohydrates and/or of the fragments of the negative ions of carbohydrates, and for each of the structures of the target carbohydrates the collision cross section value and the mass-to-charge ratio value of the negative ion thereof, and for each of the structures of the fragments of the negative ions of the target carbohydrates the collision cross section value and the mass-to-charge ratio value of the fragment of the negative ion of the target carbohydrate.Type: ApplicationFiled: September 3, 2015Publication date: August 30, 2018Applicants: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., Freie Universitat Berlin, Freie Universitat BerlinInventors: Johanna Hofmann, Heung Sik Hahm, Peter Seeberger, Kevin Pagel
-
Patent number: 10052373Abstract: The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is a Streptococcus pneumoniae type 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with Streptococcus pneumoniae, and more specifically against diseases associated with Streptococcus pneumoniae type 3.Type: GrantFiled: September 18, 2014Date of Patent: August 21, 2018Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Dominea Rathwell, Sharavathi Guddehalli Parameswarappa, Subramanian Govindan, Chakkumkal Anish, Claney Lebev Pereira, Peter H. Seeberger, Felix Bröcker
-
Publication number: 20180223302Abstract: The present invention relates to an organism, a tissue, a cell or an organelle expressing enzymes which allow the conversion of 2-phosphoglycolate (2-PG; also known as glycolate 2-phosphate) into an intermediate compound of the Calvin-Benson-Bassham Cycle (CBBC) without releasing CO2. The organism, tissue, cell or organelle of the invention may be genetically engineered, transgenic and/or transplastomic so as to express at least one enzyme which is involved in this conversion. The present invention further relates to an organism, tissue, cell or organelle which comprises/expresses at least one enzyme which is involved in this conversion. The present invention further relates to a method for producing an organism, tissue, cell or organelle of the invention. The present invention further relates to a method of enzymatically converting 2-PG into an intermediate compound of the CBBC without releasing CO2.Type: ApplicationFiled: June 22, 2016Publication date: August 9, 2018Applicants: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Yeda Research and Development Co. Ltd., at the Weizmann Institute of ScienceInventors: Arren BAR-EVEN, Tobias ERB, Steffen LINDNER, Philippe MARLIERE, Dan S. TAWFIK
-
Publication number: 20180208966Abstract: The present invention relates to an oligonucleotide comprising (a) a double-stranded portion, which double-stranded portion is DNA and 9 to 30 base in length; (b) a loop connecting the 3? end of the first strand of said double-stranded portion with the 5? end of the second strand of said double-stranded portion, said loop comprising, in 5? to 3? direction: (ba) a first DNA portion which is 4 to 20 nucleotides in length; (bb) a non-nucleic acid spacer which (i) does not interfere with the formation of a stem-loop by said oligonucleotide; and (ii) causes polymerases to cease; and (bc) a second DNA portion which is 4 to 20 nucleotides in length; wherein said first DNA portion and said second DNA portion are not complementary to each other; (c) a single-stranded overhang at its 5? end, said overhang being 5 to 40 nucleotides in length, wherein (ca) the bond connecting said double-stranded portion with the nucleotide of said overhang which is directly adjacent to said double-stranded portion is cleavable under alkType: ApplicationFiled: July 15, 2016Publication date: July 26, 2018Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.Inventors: Ibrahim Avsar ILIK, Asifa AKHTAR, Tugce Aktas ILIK
-
Patent number: 10032254Abstract: A computer-implemented method for recovering a digital image (x) from a sequence of observed digital images (y1, . . . , yT), includes: obtaining an observed digital image (yt); estimating a point spread function (ft) based on the observed image (yt); estimating the recovered digital image (x), based on the estimated point spread function (ft) and the observed image (yt); and repeating the above steps. In order to correct optical aberrations of a lens, a point spread function of the lens may be used.Type: GrantFiled: September 28, 2011Date of Patent: July 24, 2018Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Stefan Harmeling, Michael Hirsch, Suvrit Sra, Bernhard Schölkopf, Christian J. Schuler
-
Patent number: 9980907Abstract: The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C.Type: GrantFiled: June 17, 2010Date of Patent: May 29, 2018Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Hansj{hacek over (o)}rg Eibl, Lars H. Lindner